SpectraCure AB (publ) OMXSTO:SPEC:
REPORTS POSITIVE 12-MONTH RESULTS IN PROSTATE CANCER STUDY
Spectracure Reports Positive Results In Prostate Cancer Study
Story so far
Earlier from SpectraCure
- SPEC: Clinical progress and new funding strengthen position despite ongoing losses
- SPEC: Q1 2025 saw continued losses and a planned rights issue as SpectraCure advances clinical studies
- SPEC: Net loss widened as SpectraCure advanced clinical trials, with new funding needed by mid-2025
- SPEC: Losses widened in Q3 as SpectraCure advances clinical studies and seeks new funding
- SPEC: Net loss widened in H1 2024 as SpectraCure advanced Q-PRO® clinical studies and market plans
Later from SpectraCure
- Spectracure Appoints Johannes Swartling As CEO
- Spectracure Gets Approval To Commence Clinical Trial
- Spectracure Q-Pro Patent Approved In Japan
- Spectracure Signs Agreement With Cheplapharm For Verteporfin Supply
- Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
Follow SpectraCure into a list and get an email when it puts out news.
Follow SpectraCure